Review



easysep human cord blood cd34 positive selection kit ii  (STEMCELL Technologies Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    STEMCELL Technologies Inc easysep human cord blood cd34 positive selection kit ii
    NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived <t>CD34</t> + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Easysep Human Cord Blood Cd34 Positive Selection Kit Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/easysep+human+cord+blood+cd34+positive+selection+kit+ii/easysep+human+t+cell+isolation+kit/pmc12152875-160-11-20
    Average 90 stars, based on 1 article reviews
    easysep human cord blood cd34 positive selection kit ii - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells"

    Article Title: Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

    Journal: Molecular Therapy. Methods & Clinical Development

    doi: 10.1016/j.omtm.2025.101487

    NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Figure Legend Snippet: NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Techniques Used: Derivative Assay, Comparison

    NSG-Quad mice support the development of human myeloid cells (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood of NSG-Quad +/− mice (heterozygous M-CSF, n = 24) and NSG-Quad +/+ mice (homozygous M-CSF, n = 9) at 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG-Quad +/− mice ( n = 24) and NSG-Quad +/+ mice ( n = 9) 10–15 weeks post-engraftment. (C) Percentage of human immune cell subsets in the blood of NSG-Quad +/− and NSG-Quad +/+ mice 10–15 weeks post-engraftment (data from B). (D) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (E) Human immune cell composition in the blood of NSGS ( n = 11) and NSG-Quad mice ( n = 25) 10–15 weeks post-engraftment. (F) Percentage of human immune cell subsets in the blood of NSGS and NSG-Quad mice 10–15 weeks post-engraftment (data from E). Data are shown as mean ± SEM. p values were calculated using two-tailed, unpaired Student’s t test (A), two-way ANOVA with Tukey’s multiple comparison test (D) and two-tailed, unpaired Mann-Whitney U test (C, F). ∗ p < 0.05, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Figure Legend Snippet: NSG-Quad mice support the development of human myeloid cells (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood of NSG-Quad +/− mice (heterozygous M-CSF, n = 24) and NSG-Quad +/+ mice (homozygous M-CSF, n = 9) at 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG-Quad +/− mice ( n = 24) and NSG-Quad +/+ mice ( n = 9) 10–15 weeks post-engraftment. (C) Percentage of human immune cell subsets in the blood of NSG-Quad +/− and NSG-Quad +/+ mice 10–15 weeks post-engraftment (data from B). (D) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (E) Human immune cell composition in the blood of NSGS ( n = 11) and NSG-Quad mice ( n = 25) 10–15 weeks post-engraftment. (F) Percentage of human immune cell subsets in the blood of NSGS and NSG-Quad mice 10–15 weeks post-engraftment (data from E). Data are shown as mean ± SEM. p values were calculated using two-tailed, unpaired Student’s t test (A), two-way ANOVA with Tukey’s multiple comparison test (D) and two-tailed, unpaired Mann-Whitney U test (C, F). ∗ p < 0.05, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Techniques Used: Derivative Assay, Two Tailed Test, Comparison, MANN-WHITNEY

    NSG-Quad mice promote the development of tumor-infiltrating human macrophages (A) Tumor growth curves in NSG ( n = 9), NSG-Quad ( n = 12), and MISTRG-6 mice ( n = 15) engrafted with SW480 CRC cells and in NSG ( n = 10), NSG-Quad ( n = 4), and MISTRG-6 mice ( n = 14) engrafted with HCT116 CRC cells. (B) Frequency of hCD45 + cells in the tumor of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment). (C) Human immune cell composition in the blood of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment; data from G). (D) Human immune cell composition in the tumor xenografts of NSG ( n = 9, SW480; n = 10, HCT116), NSG-Quad ( n = 10, SW480; n = 3, HCT116), and MISTRG-6 mice ( n = 15, SW480; n = 12, HCT116). (E) Representative IHC pictures show SW480 CRC-infiltrating human CD68 + macrophages in NSG, NSG-Quad, and MISTRG-6 humanized mice. Scale bar: 50 μm. (F) Frequency of human CD68 + macrophages in CRC xenografts of NSG ( n = 11), NSG-Quad ( n = 7), and MISTRG-6 mice ( n = 15) analyzed by IHC. (G) Frequency of CD86 + (M1-like) and CD163 + (M2-like) human CD14 + monocytes in SW480 and HCT116 CRC xenografts of NSG-Quad ( n = 13) and MISTRG-6 mice ( n = 17). (H) Composition of the human CD33 + CD66b − myeloid cell population based on the expression of CD14, CD16, and HLA-DR in SW480 CRC xenografts of NSG-Quad ( n = 8) and MISTRG-6 ( n = 3) mice. Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (G) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.
    Figure Legend Snippet: NSG-Quad mice promote the development of tumor-infiltrating human macrophages (A) Tumor growth curves in NSG ( n = 9), NSG-Quad ( n = 12), and MISTRG-6 mice ( n = 15) engrafted with SW480 CRC cells and in NSG ( n = 10), NSG-Quad ( n = 4), and MISTRG-6 mice ( n = 14) engrafted with HCT116 CRC cells. (B) Frequency of hCD45 + cells in the tumor of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment). (C) Human immune cell composition in the blood of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment; data from G). (D) Human immune cell composition in the tumor xenografts of NSG ( n = 9, SW480; n = 10, HCT116), NSG-Quad ( n = 10, SW480; n = 3, HCT116), and MISTRG-6 mice ( n = 15, SW480; n = 12, HCT116). (E) Representative IHC pictures show SW480 CRC-infiltrating human CD68 + macrophages in NSG, NSG-Quad, and MISTRG-6 humanized mice. Scale bar: 50 μm. (F) Frequency of human CD68 + macrophages in CRC xenografts of NSG ( n = 11), NSG-Quad ( n = 7), and MISTRG-6 mice ( n = 15) analyzed by IHC. (G) Frequency of CD86 + (M1-like) and CD163 + (M2-like) human CD14 + monocytes in SW480 and HCT116 CRC xenografts of NSG-Quad ( n = 13) and MISTRG-6 mice ( n = 17). (H) Composition of the human CD33 + CD66b − myeloid cell population based on the expression of CD14, CD16, and HLA-DR in SW480 CRC xenografts of NSG-Quad ( n = 8) and MISTRG-6 ( n = 3) mice. Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (G) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

    Techniques Used: Derivative Assay, Expressing, Comparison

    Related Articles

    Isolation:

    Article Title: Human NK cells confer protection against HIV-1 infection in humanized mice
    Article Snippet: .. Human CD34 + cells were isolated from cord blood using EasySep Human Cord Blood CD34 Positive Selection Kit II (Stemcell Technologies) and were cryopreserved in IMDM containing 7.5% DMSO. ..

    Article Title: Characterization of TLR9 responsiveness in cell subsets derived from in vitro pDC differentiation of hematopoietic stem and progenitor cells
    Article Snippet: .. CD34-positive HSPCs were isolated using EasySep Human Cord Blood CD34 Positive Selection Kit II (STEMCELL Technologies, Cat. No: #17896) according to the manufacturer’s instructions. ..

    Article Title: Enrichment of transgene integrations by transient CRISPR activation of a silent reporter gene.
    Article Snippet: .. CD34+ HSPCs were acquired by initial purification of mononuclear cells by a Ficoll-Paque Plus gradient (Cytiva, Thermo Fisher Scientific), followed by isolation of CD34+ cells by immunomagnetic positive selection using the EasySep Human Cord Blood CD34 Positive Selection Kit II (STEMCELL Technologies). ..

    Article Title: Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells
    Article Snippet: .. Human CD34 + HSPCs were isolated from cord blood using an EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, #17896). .. Briefly, CD34 + cells were enriched by density gradient centrifugation using Lymphoprep (StemCell Technologies, #07861) followed by a positive magnetic selection with anti-human CD34 microbeads.

    Article Title: Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34 + cells and PD-L1 CAR-modified UCB-CD34 + -derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells
    Article Snippet: .. UCB-CD34 + cells were isolated using a RosetteSep CD34 pre-enrichment cocktail followed by CD34 + selection using an EasySep Human Cord Blood CD34 Positive Selection Kit II (17,896, Stemcell Technologies, Vancouver, BC, Canada). ..

    Article Title: Massively parallel base editing to map variant effects in human hematopoiesis.
    Article Snippet: .. Umbilical cord bloodderived CD34+ cells were isolated using the EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, 17896) cultured in StemSpan SFEM II human hematopoietic stem cell expansion media (StemCell Technologies, 02690) with 1% L-glutamine (Thermo Fisher, 25-030-081) and 1% Penicillin/Streptomycin (Life Technologies, 15140-122) and supplemented with the CC100 cytokine cocktail 100x (StemCell Technologies, 02690), 50 ng/mL TPO (PeproTech, 300-18) and 35 mM UM171 (StemCell Technologies, 72912). ..

    Article Title: More balance toward activating receptors and cytotoxic activity of NK cells ex vivo differentiated from human umbilical cord blood-derived CD34 + stem cells in comparison with peripheral blood NK cells
    Article Snippet: .. UCB-CD34 + cells were isolated using a RosetteSep CD34 pre-enrichment cocktail followed by CD34 + selection using an EasySep Human Cord Blood CD34 Positive Selection Kit II (17896, Stemcell Technologies, Vancouver, BC, Canada). .. To confirm purity, isolated cells were stained in phosphate-buffered saline (PBS) supplemented with 2 % FBS at 4 °C for 25 min with Phycoerythrin (PE)-conjugated anti-human CD34 antibody (Stemcell Technologies).

    Selection:

    Article Title: Human NK cells confer protection against HIV-1 infection in humanized mice
    Article Snippet: .. Human CD34 + cells were isolated from cord blood using EasySep Human Cord Blood CD34 Positive Selection Kit II (Stemcell Technologies) and were cryopreserved in IMDM containing 7.5% DMSO. ..

    Article Title: Characterization of TLR9 responsiveness in cell subsets derived from in vitro pDC differentiation of hematopoietic stem and progenitor cells
    Article Snippet: .. CD34-positive HSPCs were isolated using EasySep Human Cord Blood CD34 Positive Selection Kit II (STEMCELL Technologies, Cat. No: #17896) according to the manufacturer’s instructions. ..

    Article Title: Enrichment of transgene integrations by transient CRISPR activation of a silent reporter gene.
    Article Snippet: .. CD34+ HSPCs were acquired by initial purification of mononuclear cells by a Ficoll-Paque Plus gradient (Cytiva, Thermo Fisher Scientific), followed by isolation of CD34+ cells by immunomagnetic positive selection using the EasySep Human Cord Blood CD34 Positive Selection Kit II (STEMCELL Technologies). ..

    Article Title: Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells
    Article Snippet: .. Human CD34 + HSPCs were isolated from cord blood using an EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, #17896). .. Briefly, CD34 + cells were enriched by density gradient centrifugation using Lymphoprep (StemCell Technologies, #07861) followed by a positive magnetic selection with anti-human CD34 microbeads.

    Article Title: Streptavidin-drug conjugates streamline optimization of antibody-based conditioning for hematopoietic stem cell transplantation
    Article Snippet: .. For CD34 + purification, the EasySep Human Cord Blood CD34 Positive Selection Kit II (STEMCELL Technologies) was used; following the manufacturer’s protocol, CD34 + purities >90% were routinely obtained. ..

    Article Title: Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34 + cells and PD-L1 CAR-modified UCB-CD34 + -derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells
    Article Snippet: .. UCB-CD34 + cells were isolated using a RosetteSep CD34 pre-enrichment cocktail followed by CD34 + selection using an EasySep Human Cord Blood CD34 Positive Selection Kit II (17,896, Stemcell Technologies, Vancouver, BC, Canada). ..

    Article Title: Massively parallel base editing to map variant effects in human hematopoiesis.
    Article Snippet: .. Umbilical cord bloodderived CD34+ cells were isolated using the EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, 17896) cultured in StemSpan SFEM II human hematopoietic stem cell expansion media (StemCell Technologies, 02690) with 1% L-glutamine (Thermo Fisher, 25-030-081) and 1% Penicillin/Streptomycin (Life Technologies, 15140-122) and supplemented with the CC100 cytokine cocktail 100x (StemCell Technologies, 02690), 50 ng/mL TPO (PeproTech, 300-18) and 35 mM UM171 (StemCell Technologies, 72912). ..

    Article Title: More balance toward activating receptors and cytotoxic activity of NK cells ex vivo differentiated from human umbilical cord blood-derived CD34 + stem cells in comparison with peripheral blood NK cells
    Article Snippet: .. UCB-CD34 + cells were isolated using a RosetteSep CD34 pre-enrichment cocktail followed by CD34 + selection using an EasySep Human Cord Blood CD34 Positive Selection Kit II (17896, Stemcell Technologies, Vancouver, BC, Canada). .. To confirm purity, isolated cells were stained in phosphate-buffered saline (PBS) supplemented with 2 % FBS at 4 °C for 25 min with Phycoerythrin (PE)-conjugated anti-human CD34 antibody (Stemcell Technologies).

    Purification:

    Article Title: Enrichment of transgene integrations by transient CRISPR activation of a silent reporter gene.
    Article Snippet: .. CD34+ HSPCs were acquired by initial purification of mononuclear cells by a Ficoll-Paque Plus gradient (Cytiva, Thermo Fisher Scientific), followed by isolation of CD34+ cells by immunomagnetic positive selection using the EasySep Human Cord Blood CD34 Positive Selection Kit II (STEMCELL Technologies). ..

    Article Title: Streptavidin-drug conjugates streamline optimization of antibody-based conditioning for hematopoietic stem cell transplantation
    Article Snippet: .. For CD34 + purification, the EasySep Human Cord Blood CD34 Positive Selection Kit II (STEMCELL Technologies) was used; following the manufacturer’s protocol, CD34 + purities >90% were routinely obtained. ..

    Cell Culture:

    Article Title: Massively parallel base editing to map variant effects in human hematopoiesis.
    Article Snippet: .. Umbilical cord bloodderived CD34+ cells were isolated using the EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, 17896) cultured in StemSpan SFEM II human hematopoietic stem cell expansion media (StemCell Technologies, 02690) with 1% L-glutamine (Thermo Fisher, 25-030-081) and 1% Penicillin/Streptomycin (Life Technologies, 15140-122) and supplemented with the CC100 cytokine cocktail 100x (StemCell Technologies, 02690), 50 ng/mL TPO (PeproTech, 300-18) and 35 mM UM171 (StemCell Technologies, 72912). ..



    Similar Products

    easysep human cord blood cd34 positive selection kit ii  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc easysep human cord blood cd34 positive selection kit ii
    NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived <t>CD34</t> + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Easysep Human Cord Blood Cd34 Positive Selection Kit Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/easysep+human+cord+blood+cd34+positive+selection+kit+ii/easysep+human+t+cell+isolation+kit/pmc12152875-160-11-20
    Average 90 stars, based on 1 article reviews
    easysep human cord blood cd34 positive selection kit ii - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    easysep human cord blood cd34-positive selection kit ii  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc easysep human cord blood cd34-positive selection kit ii
    NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived <t>CD34</t> + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
    Easysep Human Cord Blood Cd34 Positive Selection Kit Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/easysep+human+cord+blood+cd34+positive+selection+kit+ii/easysep+human+t+cell+isolation+kit/pm38091132-29-19-27
    Average 90 stars, based on 1 article reviews
    easysep human cord blood cd34-positive selection kit ii - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    easysep tm human cord blood cd34 positive selection kit ii  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc easysep tm human cord blood cd34 positive selection kit ii
    (A) Marker expression of independently cultured monolayers of hFOB and two BMSC donors as determined by flow cytometry, n = 4. (B) Cartoon schematic of experimental design. Cord blood-derived endothelial cells (EC) seeded with either hFOB (OB, Endosteal Niche) or BMSC (Perivascular Niche) form microvascular networks in a period of 4–7 days. (C) BMoaC cultured with CellTracker™ Violet hFOB and Deep Red BMSC demonstrated stromal separation by niche. (D) Relative fluorescent area (RFA) of Violet hFOB in the endosteal niche compared to unstained BMSC within the perivascular niche and RFA of unstained hFOB in the endosteal niche to Deep Red BMSC in the perivascular niche. Fluorescent area was determined by normalizing to an unstained control. *p < 0.05, ***p < 0.001 by two-way ANOVA. (E) Osteopontin (green) was expressed in the (i) endosteal and (ii) perivascular niches. EC (red) counterstained with <t>CD34.</t> (F) SDF-1 was detected adjacent to EC (red) in the (i) endosteal niche with enhanced expression of SDF-1 in the (ii) perivascular niche. (G) EC (red) were adjacent to stromal cells that express leptin as seen in the (i) endosteal and (ii) perivascular niche. Nuclei counterstained with DAPI (blue). Scale bars: 500 μm and 50 μm for low and high magnification images, respectively.
    Easysep Tm Human Cord Blood Cd34 Positive Selection Kit Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/easysep+human+cord+blood+cd34+positive+selection+kit+ii/easysep+human+t+cell+isolation+kit/pmc10658812-91-11-21
    Average 90 stars, based on 1 article reviews
    easysep tm human cord blood cd34 positive selection kit ii - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    easysep™ human cord blood cd34 positive selection kit ii  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc easysep™ human cord blood cd34 positive selection kit ii
    a, b , Strategy for generating CARD8-edited humanized mice. Blood samples were collected 10 weeks after the transplantation to determine the frequency of CARD8 editing by sequencing analysis. c, d , Human immune cell reconstitution and T cell development in mice engrafted with CARD8 -KO or Cas9 control <t>CD34</t> + cells. Blood samples were collected 10 weeks after transplantation. e , Plasma viral loads was measured two weeks after infection. f, g , The frequency and number of human CD4 + T cells in tissues. In b-f, data were pooled from three independent mouse cohorts. Cas9 ctrl, N=17, except for lung (N=16); CARD8 -KO, N=18. In g , data were pooled from two of the three independent mouse cohorts mentioned above. Cas9 ctrl, N=11, except for lung (N=10); CARD8 -KO, N=12. p values were calculated using an unpaired t-test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Error bars show mean values with SEM.
    Easysep™ Human Cord Blood Cd34 Positive Selection Kit Ii, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/easysep+human+cord+blood+cd34+positive+selection+kit+ii/easysep+human+t+cell+isolation+kit/bio_rxiv__2023__03__18__533283-110-10-19
    Average 90 stars, based on 1 article reviews
    easysep™ human cord blood cd34 positive selection kit ii - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

    doi: 10.1016/j.omtm.2025.101487

    Figure Lengend Snippet: NSG-Quad mice support human hematopoietic cell engraftment and multilineage immune cell development (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG ( n = 33), NSG-Quad ( n = 34), and MISTRG-6 mice ( n = 32) 8 weeks post-engraftment and in the blood of NSG ( n = 29), NSG-Quad ( n = 25), and MISTRG-6 mice ( n = 16) 10–15 weeks post-engraftment. B cells (CD3 − CD56 − CD33 − CD20 + ), myeloid cells (CD3 − CD56 − CD20 − CD33 + ), NK cells (CD3 − CD56 + ), CD8 + T cells (CD3 + CD4 − CD8 + ), and CD4 + T cells (CD3 + CD8 − CD4 + ). (C) Percentage of human immune cell subsets in the blood 8 weeks post-engraftment (data from B). (D) Percentage of human immune cell subsets in the blood 10–15 weeks post-engraftment (data from B). Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (A) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Article Snippet: Human CD34 + HSPCs were isolated from cord blood using an EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, #17896).

    Techniques: Derivative Assay, Comparison

    NSG-Quad mice support the development of human myeloid cells (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood of NSG-Quad +/− mice (heterozygous M-CSF, n = 24) and NSG-Quad +/+ mice (homozygous M-CSF, n = 9) at 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG-Quad +/− mice ( n = 24) and NSG-Quad +/+ mice ( n = 9) 10–15 weeks post-engraftment. (C) Percentage of human immune cell subsets in the blood of NSG-Quad +/− and NSG-Quad +/+ mice 10–15 weeks post-engraftment (data from B). (D) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (E) Human immune cell composition in the blood of NSGS ( n = 11) and NSG-Quad mice ( n = 25) 10–15 weeks post-engraftment. (F) Percentage of human immune cell subsets in the blood of NSGS and NSG-Quad mice 10–15 weeks post-engraftment (data from E). Data are shown as mean ± SEM. p values were calculated using two-tailed, unpaired Student’s t test (A), two-way ANOVA with Tukey’s multiple comparison test (D) and two-tailed, unpaired Mann-Whitney U test (C, F). ∗ p < 0.05, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

    doi: 10.1016/j.omtm.2025.101487

    Figure Lengend Snippet: NSG-Quad mice support the development of human myeloid cells (A) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood of NSG-Quad +/− mice (heterozygous M-CSF, n = 24) and NSG-Quad +/+ mice (homozygous M-CSF, n = 9) at 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (B) Human immune cell composition in the blood of NSG-Quad +/− mice ( n = 24) and NSG-Quad +/+ mice ( n = 9) 10–15 weeks post-engraftment. (C) Percentage of human immune cell subsets in the blood of NSG-Quad +/− and NSG-Quad +/+ mice 10–15 weeks post-engraftment (data from B). (D) Percentage of human CD45 + (hCD45 + ) cells of total CD45 + cells (mouse and human) in the blood at 8 weeks and 10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells. (E) Human immune cell composition in the blood of NSGS ( n = 11) and NSG-Quad mice ( n = 25) 10–15 weeks post-engraftment. (F) Percentage of human immune cell subsets in the blood of NSGS and NSG-Quad mice 10–15 weeks post-engraftment (data from E). Data are shown as mean ± SEM. p values were calculated using two-tailed, unpaired Student’s t test (A), two-way ANOVA with Tukey’s multiple comparison test (D) and two-tailed, unpaired Mann-Whitney U test (C, F). ∗ p < 0.05, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

    Article Snippet: Human CD34 + HSPCs were isolated from cord blood using an EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, #17896).

    Techniques: Derivative Assay, Two Tailed Test, Comparison, MANN-WHITNEY

    NSG-Quad mice promote the development of tumor-infiltrating human macrophages (A) Tumor growth curves in NSG ( n = 9), NSG-Quad ( n = 12), and MISTRG-6 mice ( n = 15) engrafted with SW480 CRC cells and in NSG ( n = 10), NSG-Quad ( n = 4), and MISTRG-6 mice ( n = 14) engrafted with HCT116 CRC cells. (B) Frequency of hCD45 + cells in the tumor of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment). (C) Human immune cell composition in the blood of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment; data from G). (D) Human immune cell composition in the tumor xenografts of NSG ( n = 9, SW480; n = 10, HCT116), NSG-Quad ( n = 10, SW480; n = 3, HCT116), and MISTRG-6 mice ( n = 15, SW480; n = 12, HCT116). (E) Representative IHC pictures show SW480 CRC-infiltrating human CD68 + macrophages in NSG, NSG-Quad, and MISTRG-6 humanized mice. Scale bar: 50 μm. (F) Frequency of human CD68 + macrophages in CRC xenografts of NSG ( n = 11), NSG-Quad ( n = 7), and MISTRG-6 mice ( n = 15) analyzed by IHC. (G) Frequency of CD86 + (M1-like) and CD163 + (M2-like) human CD14 + monocytes in SW480 and HCT116 CRC xenografts of NSG-Quad ( n = 13) and MISTRG-6 mice ( n = 17). (H) Composition of the human CD33 + CD66b − myeloid cell population based on the expression of CD14, CD16, and HLA-DR in SW480 CRC xenografts of NSG-Quad ( n = 8) and MISTRG-6 ( n = 3) mice. Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (G) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: Comparison of NSG-Quad and MISTRG-6 humanized mice for modeling circulating and tumor-infiltrating human myeloid cells

    doi: 10.1016/j.omtm.2025.101487

    Figure Lengend Snippet: NSG-Quad mice promote the development of tumor-infiltrating human macrophages (A) Tumor growth curves in NSG ( n = 9), NSG-Quad ( n = 12), and MISTRG-6 mice ( n = 15) engrafted with SW480 CRC cells and in NSG ( n = 10), NSG-Quad ( n = 4), and MISTRG-6 mice ( n = 14) engrafted with HCT116 CRC cells. (B) Frequency of hCD45 + cells in the tumor of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment). (C) Human immune cell composition in the blood of NSG, NSG-Quad, and MISTRG-6 humanized mice engrafted with SW480 or HCT116 CRC cells (10–15 weeks post-engraftment with human-cord-blood-derived CD34 + cells; end of experiment; data from G). (D) Human immune cell composition in the tumor xenografts of NSG ( n = 9, SW480; n = 10, HCT116), NSG-Quad ( n = 10, SW480; n = 3, HCT116), and MISTRG-6 mice ( n = 15, SW480; n = 12, HCT116). (E) Representative IHC pictures show SW480 CRC-infiltrating human CD68 + macrophages in NSG, NSG-Quad, and MISTRG-6 humanized mice. Scale bar: 50 μm. (F) Frequency of human CD68 + macrophages in CRC xenografts of NSG ( n = 11), NSG-Quad ( n = 7), and MISTRG-6 mice ( n = 15) analyzed by IHC. (G) Frequency of CD86 + (M1-like) and CD163 + (M2-like) human CD14 + monocytes in SW480 and HCT116 CRC xenografts of NSG-Quad ( n = 13) and MISTRG-6 mice ( n = 17). (H) Composition of the human CD33 + CD66b − myeloid cell population based on the expression of CD14, CD16, and HLA-DR in SW480 CRC xenografts of NSG-Quad ( n = 8) and MISTRG-6 ( n = 3) mice. Data are shown as mean ± SEM. p values were calculated using one-way or two-way ANOVA (G) with Tukey’s multiple comparison test. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

    Article Snippet: Human CD34 + HSPCs were isolated from cord blood using an EasySep Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies, #17896).

    Techniques: Derivative Assay, Expressing, Comparison

    (A) Marker expression of independently cultured monolayers of hFOB and two BMSC donors as determined by flow cytometry, n = 4. (B) Cartoon schematic of experimental design. Cord blood-derived endothelial cells (EC) seeded with either hFOB (OB, Endosteal Niche) or BMSC (Perivascular Niche) form microvascular networks in a period of 4–7 days. (C) BMoaC cultured with CellTracker™ Violet hFOB and Deep Red BMSC demonstrated stromal separation by niche. (D) Relative fluorescent area (RFA) of Violet hFOB in the endosteal niche compared to unstained BMSC within the perivascular niche and RFA of unstained hFOB in the endosteal niche to Deep Red BMSC in the perivascular niche. Fluorescent area was determined by normalizing to an unstained control. *p < 0.05, ***p < 0.001 by two-way ANOVA. (E) Osteopontin (green) was expressed in the (i) endosteal and (ii) perivascular niches. EC (red) counterstained with CD34. (F) SDF-1 was detected adjacent to EC (red) in the (i) endosteal niche with enhanced expression of SDF-1 in the (ii) perivascular niche. (G) EC (red) were adjacent to stromal cells that express leptin as seen in the (i) endosteal and (ii) perivascular niche. Nuclei counterstained with DAPI (blue). Scale bars: 500 μm and 50 μm for low and high magnification images, respectively.

    Journal: Biomaterials

    Article Title: Organ-on-a-chip model of vascularized human bone marrow niches

    doi: 10.1016/j.biomaterials.2021.121245

    Figure Lengend Snippet: (A) Marker expression of independently cultured monolayers of hFOB and two BMSC donors as determined by flow cytometry, n = 4. (B) Cartoon schematic of experimental design. Cord blood-derived endothelial cells (EC) seeded with either hFOB (OB, Endosteal Niche) or BMSC (Perivascular Niche) form microvascular networks in a period of 4–7 days. (C) BMoaC cultured with CellTracker™ Violet hFOB and Deep Red BMSC demonstrated stromal separation by niche. (D) Relative fluorescent area (RFA) of Violet hFOB in the endosteal niche compared to unstained BMSC within the perivascular niche and RFA of unstained hFOB in the endosteal niche to Deep Red BMSC in the perivascular niche. Fluorescent area was determined by normalizing to an unstained control. *p < 0.05, ***p < 0.001 by two-way ANOVA. (E) Osteopontin (green) was expressed in the (i) endosteal and (ii) perivascular niches. EC (red) counterstained with CD34. (F) SDF-1 was detected adjacent to EC (red) in the (i) endosteal niche with enhanced expression of SDF-1 in the (ii) perivascular niche. (G) EC (red) were adjacent to stromal cells that express leptin as seen in the (i) endosteal and (ii) perivascular niche. Nuclei counterstained with DAPI (blue). Scale bars: 500 μm and 50 μm for low and high magnification images, respectively.

    Article Snippet: HSPC (CD34 + ) were isolated from cord blood using the EasySep TM Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies) according to the manufacturer’s guidelines.

    Techniques: Marker, Expressing, Cell Culture, Flow Cytometry, Derivative Assay, Control

    (A)–(F) Endothelial cell (red, CD31 or CD34) (A) laminin in the basement membrane, (B) SCF, (C) I-CAM, (D) V-CAM, (E) E-Selectin/CD62E and (F) Nestin. ROIs show z-stacks in either the (i) endosteal or (ii) perivascular niche. Nuclei were counterstained with DAPI (Blue). Scale bars: 500 μm and 50 μm for low and high magnification views, respectively. (G) BMoaC microvascular networks were i) perfused with 70 kDA TRITC-dextran and ii) had permeabilities of 16.96 × 10−7 cm/s and 5.19 × 10−7 cm/s for the endosteal (n = 3) and perivascular niches (n = 5), respectively.

    Journal: Biomaterials

    Article Title: Organ-on-a-chip model of vascularized human bone marrow niches

    doi: 10.1016/j.biomaterials.2021.121245

    Figure Lengend Snippet: (A)–(F) Endothelial cell (red, CD31 or CD34) (A) laminin in the basement membrane, (B) SCF, (C) I-CAM, (D) V-CAM, (E) E-Selectin/CD62E and (F) Nestin. ROIs show z-stacks in either the (i) endosteal or (ii) perivascular niche. Nuclei were counterstained with DAPI (Blue). Scale bars: 500 μm and 50 μm for low and high magnification views, respectively. (G) BMoaC microvascular networks were i) perfused with 70 kDA TRITC-dextran and ii) had permeabilities of 16.96 × 10−7 cm/s and 5.19 × 10−7 cm/s for the endosteal (n = 3) and perivascular niches (n = 5), respectively.

    Article Snippet: HSPC (CD34 + ) were isolated from cord blood using the EasySep TM Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies) according to the manufacturer’s guidelines.

    Techniques: Membrane

    (A) Experimental design. (B) (i) CD34+ cells isolated from human cord blood were 90.4% ± 6.37 CD34+ and 78.4% ± 8.57 CD34+/CD133+, n = 14. (ii) Approximately 40–60 CD34+ HSPC were loaded into each device, n = 21 devices. (C) BMoaC supported CD34+ blood vessels. (i,ii) Small, round CD34+ HSPC (arrows) were present along with Lin+ cells. Scale bars: 500 μm and 50 μm for low and high magnification images, respectively. (D) Cells isolated after 7, 10, and 14 days of culture in the BMoaC were analyzed for CD34/CD133 from both the endosteal and perivascular niches, biological replicates with n = 5. (E) Cells isolated after 7, 10, and 14 days of culture from either niche in the BMoaC consistently generated CFU-GEMM, biological replicates with n = 10–11. (F) Cells isolated after 10 and 14 days of culture within single niche (SN, endosteal or perivascular) controls produced CFU-GEMM; monolayer controls did not.

    Journal: Biomaterials

    Article Title: Organ-on-a-chip model of vascularized human bone marrow niches

    doi: 10.1016/j.biomaterials.2021.121245

    Figure Lengend Snippet: (A) Experimental design. (B) (i) CD34+ cells isolated from human cord blood were 90.4% ± 6.37 CD34+ and 78.4% ± 8.57 CD34+/CD133+, n = 14. (ii) Approximately 40–60 CD34+ HSPC were loaded into each device, n = 21 devices. (C) BMoaC supported CD34+ blood vessels. (i,ii) Small, round CD34+ HSPC (arrows) were present along with Lin+ cells. Scale bars: 500 μm and 50 μm for low and high magnification images, respectively. (D) Cells isolated after 7, 10, and 14 days of culture in the BMoaC were analyzed for CD34/CD133 from both the endosteal and perivascular niches, biological replicates with n = 5. (E) Cells isolated after 7, 10, and 14 days of culture from either niche in the BMoaC consistently generated CFU-GEMM, biological replicates with n = 10–11. (F) Cells isolated after 10 and 14 days of culture within single niche (SN, endosteal or perivascular) controls produced CFU-GEMM; monolayer controls did not.

    Article Snippet: HSPC (CD34 + ) were isolated from cord blood using the EasySep TM Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies) according to the manufacturer’s guidelines.

    Techniques: Isolation, Generated, Produced

    (A) After 10 days of culture, BMoaC contain cells expressing CD14 (Green) in both sides of the device and in the (i, ii) lumen of CD34+ blood vessels (red). Nuclei were counterstained with DAPI (blue). Scale bars: 500 μm and 50 μm for low and high magnification images, respectively. Cells that egressed from the bone marrow niche and into the adjacent fluidic line of devices were collected on Day 14 and analyzed by flow cytometry for (B) the leukocyte common antigen CD45 and (C) the myeloid marker CD33 and neutrophil marker CD66b. (D) BMoaC exposed to 0.5 M doxorubicin between days 8 and 10 of a 14 day culture produce significantly fewer egressed CD66b+/CD33− cells from the perivascular niche compared to control devices. **p < 0.01 by 2-way ANOVA followed by Sidak’s post hoc-analysis. (E) BMoaC exposed to 30 ng/mL G-CSF produced significantly more egressed CD66b+/CD33− cells from the perivascular niche compared to control devices. *p < 0.05, **p < 0.01 by 2-way ANOVA followed by Tukey’s post hoc-analysis.

    Journal: Biomaterials

    Article Title: Organ-on-a-chip model of vascularized human bone marrow niches

    doi: 10.1016/j.biomaterials.2021.121245

    Figure Lengend Snippet: (A) After 10 days of culture, BMoaC contain cells expressing CD14 (Green) in both sides of the device and in the (i, ii) lumen of CD34+ blood vessels (red). Nuclei were counterstained with DAPI (blue). Scale bars: 500 μm and 50 μm for low and high magnification images, respectively. Cells that egressed from the bone marrow niche and into the adjacent fluidic line of devices were collected on Day 14 and analyzed by flow cytometry for (B) the leukocyte common antigen CD45 and (C) the myeloid marker CD33 and neutrophil marker CD66b. (D) BMoaC exposed to 0.5 M doxorubicin between days 8 and 10 of a 14 day culture produce significantly fewer egressed CD66b+/CD33− cells from the perivascular niche compared to control devices. **p < 0.01 by 2-way ANOVA followed by Sidak’s post hoc-analysis. (E) BMoaC exposed to 30 ng/mL G-CSF produced significantly more egressed CD66b+/CD33− cells from the perivascular niche compared to control devices. *p < 0.05, **p < 0.01 by 2-way ANOVA followed by Tukey’s post hoc-analysis.

    Article Snippet: HSPC (CD34 + ) were isolated from cord blood using the EasySep TM Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies) according to the manufacturer’s guidelines.

    Techniques: Expressing, Flow Cytometry, Marker, Control, Produced

    (A) Experimental design. Breast cancer cells were loaded into the bottom chamber of the BMoaC on Day 4 and cultured for an additional 8 days. (B) The triple negative breast cancer cell line MDA-MB-231 (green) proliferated over time and migrated into the bottom portion of both the endosteal and perivascular niches. EC and HSPC (red) were labeled with CD34 antibody and nuclei (blue) were counterstained with DAPI. Scale bar: 500 μm. The fluorescent area of cancer cells in each chamber of the device was quantified. (C) MDA-MB-231 cells migrated towards the endosteal and perivascular niches after 8 days of culture in the BMoaC. (D) MDA-MB-231 cancer cells in the BMoaC perivascular and endosteal niches versus fibrin only controls expressed significantly more Ki-67, suggesting active proliferation. Cancer cells in the BMoaC perivascular niche expressed more Ki-67 than those in the bottom chamber. *p < 0.05, **p < 0.01, ***p < 0.001 by 2-way ANOVA followed by Tukey’s post hoc-analysis.

    Journal: Biomaterials

    Article Title: Organ-on-a-chip model of vascularized human bone marrow niches

    doi: 10.1016/j.biomaterials.2021.121245

    Figure Lengend Snippet: (A) Experimental design. Breast cancer cells were loaded into the bottom chamber of the BMoaC on Day 4 and cultured for an additional 8 days. (B) The triple negative breast cancer cell line MDA-MB-231 (green) proliferated over time and migrated into the bottom portion of both the endosteal and perivascular niches. EC and HSPC (red) were labeled with CD34 antibody and nuclei (blue) were counterstained with DAPI. Scale bar: 500 μm. The fluorescent area of cancer cells in each chamber of the device was quantified. (C) MDA-MB-231 cells migrated towards the endosteal and perivascular niches after 8 days of culture in the BMoaC. (D) MDA-MB-231 cancer cells in the BMoaC perivascular and endosteal niches versus fibrin only controls expressed significantly more Ki-67, suggesting active proliferation. Cancer cells in the BMoaC perivascular niche expressed more Ki-67 than those in the bottom chamber. *p < 0.05, **p < 0.01, ***p < 0.001 by 2-way ANOVA followed by Tukey’s post hoc-analysis.

    Article Snippet: HSPC (CD34 + ) were isolated from cord blood using the EasySep TM Human Cord Blood CD34 Positive Selection Kit II (StemCell Technologies) according to the manufacturer’s guidelines.

    Techniques: Cell Culture, Labeling

    a, b , Strategy for generating CARD8-edited humanized mice. Blood samples were collected 10 weeks after the transplantation to determine the frequency of CARD8 editing by sequencing analysis. c, d , Human immune cell reconstitution and T cell development in mice engrafted with CARD8 -KO or Cas9 control CD34 + cells. Blood samples were collected 10 weeks after transplantation. e , Plasma viral loads was measured two weeks after infection. f, g , The frequency and number of human CD4 + T cells in tissues. In b-f, data were pooled from three independent mouse cohorts. Cas9 ctrl, N=17, except for lung (N=16); CARD8 -KO, N=18. In g , data were pooled from two of the three independent mouse cohorts mentioned above. Cas9 ctrl, N=11, except for lung (N=10); CARD8 -KO, N=12. p values were calculated using an unpaired t-test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Error bars show mean values with SEM.

    Journal: bioRxiv

    Article Title: The CARD8 inflammasome drives CD4 + T-cell depletion in HIV-1 infection

    doi: 10.1101/2023.03.18.533283

    Figure Lengend Snippet: a, b , Strategy for generating CARD8-edited humanized mice. Blood samples were collected 10 weeks after the transplantation to determine the frequency of CARD8 editing by sequencing analysis. c, d , Human immune cell reconstitution and T cell development in mice engrafted with CARD8 -KO or Cas9 control CD34 + cells. Blood samples were collected 10 weeks after transplantation. e , Plasma viral loads was measured two weeks after infection. f, g , The frequency and number of human CD4 + T cells in tissues. In b-f, data were pooled from three independent mouse cohorts. Cas9 ctrl, N=17, except for lung (N=16); CARD8 -KO, N=18. In g , data were pooled from two of the three independent mouse cohorts mentioned above. Cas9 ctrl, N=11, except for lung (N=10); CARD8 -KO, N=12. p values were calculated using an unpaired t-test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Error bars show mean values with SEM.

    Article Snippet: Human CD34 + cells were isolated from cord blood using EasySep™ human cord blood CD34 positive selection kit II (STEMCELL Technologies #17896), which were then cryopreserved in Iscove’s Modified Dulbecco’s Medium (IMDM, Sigma #S0192) containing 7.5% DMSO.

    Techniques: Transplantation Assay, Sequencing, Infection